Idioma:

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Gul, Anita ; Stewart, Tyler F ; Mantia, Charlene M ; Shah, Neil J ; Gatof, Emily Stern ; Long, Ying ; Allman, Kimberly D ; Ornstein, Moshe C ; Hammers, Hans J ; McDermott, David F ; Atkins, Michael B ; Hurwitz, Michael ; Rini, Brian I

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por

Enviar para

Título:
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Autor: Gul, Anita ; Stewart, Tyler F ; Mantia, Charlene M ; Shah, Neil J ; Gatof, Emily Stern ; Long, Ying ; Allman, Kimberly D ; Ornstein, Moshe C ; Hammers, Hans J ; McDermott, David F ; Atkins, Michael B ; Hurwitz, Michael ; Rini, Brian I
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B7-H1 Antigen - antagonists & inhibitors ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - secondary ; Disease Progression ; Female ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Ipilimumab - administration & dosage ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Male ; Middle Aged ; Nivolumab - administration & dosage ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Progression-Free Survival ; RAPID COMMUNICATIONS ; Retreatment ; Retrospective Studies ; Salvage Therapy ; Young Adult
É parte de: Journal of clinical oncology, 2020-09, Vol.38 (27), p.3088-3094
Descrição: Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy. Patients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed. Forty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients. Ipilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.
Editor: United States: American Society of Clinical Oncology
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

Gul, Anita ; Stewart, Tyler F ; Mantia, Charlene M ; Shah, Neil J ; Gatof, Emily Stern ; Long, Ying ; Allman, Kimberly D ; Ornstein, Moshe C ; Hammers, Hans J ; McDermott, David F ; Atkins, Michael B ; Hurwitz, Michael ; Rini, Brian I

United States: American Society of Clinical Oncology

Buscando em bases de dados remotas. Favor aguardar.